Alan Shaw’s insider trading and holdings in Codexis have seen notable ups and downs. His stock holdings peaked at about $6.60 million in January 2021, showcasing significant confidence in Codexis's future. However, after reaching this high point, the value of...
Alan Shaw’s insider trading and holdings in Codexis have seen notable ups and downs. His stock holdings peaked at about $6.60 million in January 2021, showcasing significant confidence in Codexis's future. However, after reaching this high point, the value of his holdings steadily declined over the next couple of years. As of September 2023, the value of his holdings had dropped to approximately $1.65 million. This fluctuation highlights the volatile nature of biotech stocks and how they are often influenced by company performance and market conditions. Shaw's involvement in these trades shows not only his deep connection to the company's success but also the risks that come with investing in high-growth industries.